Distribution of FK 506 in plasma lipoproteins in transplant patients.
نویسندگان
چکیده
FK 506, a powerful. new immunosuppressive agent, is currently undergoing clinical trials in transplant patients. Like cyclosporine (CyA). FK 506 suppresses interleukin-2 production and receptor expression on T cells. 1.2 Additionally, both FK 506 and CyA are highly lipophilic. 3 CyA is mainly transported by lipoproteins in plasma.4 The objective of the present study is to characterize the distribution of FK 506 in various plasma components.
منابع مشابه
Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.
OBJECTIVES We studied rejection, allograft function and side effects, such as hypertension, renal dysfunction and hypercholesterolemia, in seven patients switched from cyclosporine-based triple-drug immunosuppression to FK 506. BACKGROUND A subset of pediatric heart transplant recipients treated with triple-drug immunosuppression consisting of cyclosporine, azathioprine and prednisone experie...
متن کاملCorrelation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection.
FK 506, a novel immunosuppressive agent, was first used to reverse rejection in liver recipients who had failed to respond to conventional therapy.' The successful outcome of the initial study has led to clinical trials of FK 506 as the primary immunosuppressive agent for liver allografts and other organ transplants. 2-4 Ongoing studies include dosage protocols for optimal immunosuppression wit...
متن کاملIntravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients.
FK 506 is a new macrolide with potent immunosuppressive activity. Use of this drug is associated with reduced incidence of rejection following liver. kidney. and heart transplantation. 1-4 Recently, FK 506 has been shown to be effective in small bowel transplantation. S It is known that FK 506 absorption is not influenced by the presence or absence of bile.6--8 The aims of this study are to: (\...
متن کاملBioassay of Plasma Specimens
L IVER transplantation has been increasingly used to treat end-stage liver diseases since the introduction of Cy A in combination with other immunosuppressive agents. 1 Although Cy A has a powerful immunosuppressive effect on allograft rejection, many transplant recipients still experience rejection episodes that are often irreversible. The nephrotoxicity of Cy A in some recipients has necessit...
متن کاملFK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication.
F K 506 is a powerful new investigational immunosup-. pressant that has been used successfully first as an organ rescue agent and then as a primary antirejection agent. FK 506 has been shown to have a favorable profile on pancreatic islets in vitro'; however, the agent does decrease glucose-induced insulin release at high concentrations from bo~ rodent 2 • 3 and human islets. 2 This agent also ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Transplantation proceedings
دوره 23 1 Pt 2 شماره
صفحات -
تاریخ انتشار 1991